{"id":1904,"date":"2022-03-14T10:00:06","date_gmt":"2022-03-14T09:00:06","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=1904"},"modified":"2022-03-14T10:01:22","modified_gmt":"2022-03-14T09:01:22","slug":"a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/","title":{"rendered":"A new therapeutic strategy with selective N- glycosylation inhibitors?"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;A first-in-human research protocol investigates the effects of membrane proteins glycosylation inhibitors&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Submitted to competent authorities an innovative clinical trial that could open new avenues for solid tumors therapy, introducing treatment strategies different from those known so far.<\/p>\n<p>The study is sponsored by <strong>Phost\u2019In Therapeutics<\/strong>, a biotechnology company founded in 2014 as concretization of ten years of academic works, and led by a consortium of clinician and researchers in Montpellier and Paris, with the scientific contribution of <strong>Gianni Bonadonna Foundation<\/strong>, which collaborated in the conception and design of the research protocol.<\/p>\n<p>Diego Tosi, Gianni Bonadonna Foundation\u2019s scientific coordinator and head of the Early Clinical Trial Unit &#8211; Medical Oncology Department of the Cancer Institute of Montpellier in France, has been entrusted with the international direction of this first-in-human clinical trial, conducted in French and Italian Oncological Centers, and aimed to investigate the possibility of targeting tumors with a selective N-glycosylation inhibitor.<br \/>\nIn the field glyco-immuno-oncology aberrant glycosylation of cancer cells is now recognized as a new immune checkpoint: the process modifies membrane proteins and also seems to contribute to &#8216;masking&#8217; cancer cells from the immune system via the formation of complex abnormal glycan patterns operating as a shield. Hence the idea of using a selective N-glycosylation inhibitor for a double antitumor effect, inducing simultaneously the down regulation of the main receptors implicated in cancer and an anti-cancer immune response. \u00abThis is the first drug with this type of approach\u00bb, Diego Tosi explains. \u00abThe antitumor action seems possible mostly thanks to the effect on the membrane receptors and seems to be able to reduce disease aggressiveness; there are less data on how the immune response is modified, but our research will try to find answers\u00bb.<br \/>\nThe clinical study protocol has been defined and patient recruitment is expected to begin in early 2022; in a first dose escalation phase 21 patients with solid tumors will be involved, then a second phase will enroll patients with specific tumors such as glioblastoma multiforme (GBM), triple negative breast cancer, for which few therapeutic options exist, and other solid tumors that will be selected by the Protocol Steering Committee after the conclusion of the dose escalation phase. The primary objective will be to determine the safety and tolerability of the drug, the secondary objectives will be the characterization of the pharmacokinetic profile and a preliminary evaluation of the potential efficacy, in addition to the identification of biomarkers useful for predicting and monitoring the patients clinical response. \u00abEven if the drug production is simple, a scale-up is always complex, and we will need significant quantities of the inhibitor: there are some significant challenges, but this is a very interesting strategy to investigate\u00bb, Tosi says.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;1908&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;A first-in-human research protocol investigates the effects of membrane proteins glycosylation inhibitors&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Submitted to competent authorities an innovative clinical trial that could open<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":1908,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-1904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-14T09:00:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-14T09:01:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"A new therapeutic strategy with selective N- glycosylation inhibitors?\",\"datePublished\":\"2022-03-14T09:00:06+00:00\",\"dateModified\":\"2022-03-14T09:01:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/\"},\"wordCount\":505,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/shutterstock_536117293.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/\",\"name\":\"A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/shutterstock_536117293.jpg\",\"datePublished\":\"2022-03-14T09:00:06+00:00\",\"dateModified\":\"2022-03-14T09:01:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/shutterstock_536117293.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/shutterstock_536117293.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A new therapeutic strategy with selective N- glycosylation inhibitors?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna","description":"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna","og_description":"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2022-03-14T09:00:06+00:00","article_modified_time":"2022-03-14T09:01:22+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"A new therapeutic strategy with selective N- glycosylation inhibitors?","datePublished":"2022-03-14T09:00:06+00:00","dateModified":"2022-03-14T09:01:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/"},"wordCount":505,"commentCount":0,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/","name":"A new therapeutic strategy with selective N- glycosylation inhibitors? - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg","datePublished":"2022-03-14T09:00:06+00:00","dateModified":"2022-03-14T09:01:22+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Un protocollo di ricerca indaga per la prima volta nell\u2019uomo gli effetti di farmaci diretti contro la glicosilazione di proteine di membrana","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/03\/shutterstock_536117293.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"A new therapeutic strategy with selective N- glycosylation inhibitors?"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=1904"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1904\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/1908"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=1904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=1904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=1904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}